May 31: Mumbai-based pharma major Lupin Ltd on Thursday announced the launch of its Solosec (secnidazole) 2g oral granules in the US market, having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Last year, Lupin announced that its US subsidiary, Lupin, Inc., acquired Symbiomix Therapeutics, LLC, a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences.
Lupin’s Solosec (secnidazole) 2g oral granules are a 5-nitroimidazole antimicrobial agent indicated for the treatment of bacterial vaginosis (BV) in adult women.
“Solosec, the first new oral antibiotic to treat BV in more than a decade, is designed to deliver a full course of therapy in a single 2g oral dose and is the first and only single-dose oral therapy for BV, the most common vaginal infection in the U S among women of childbearing age,” the company said.
“New, single oral-dose Solosec was designed to be a simpler solution for patients with BV. BV affects 21 million women aged 14 to 49 annually,” it added.
“With more than four million women treated for BV in the US annually, and only 50% completing 5 to 7 day treatments, there is a clear need for an effective, single-dose oral treatment,” said Vinita Gupta, Chief Executive Officer, Lupin Ltd. “We are proud that Lupin has been at the forefront of advancing safe and affordable healthcare for women globally for decades, and we are committed to helping prevent and manage women’s health conditions with serious consequences, including BV.”
Lupin shares were trading in red at Rs 774.20, down 0.52% from the previous closing of Rs 778.25, on BSE at 12.55 pm today.